In a fluorescent microscope image from Toronto’s SickKids Hospital, green-lit cells reveal a malfunctioning gene—BIRC3—now linked to Crohn’s disease in 14 children across 10 families worldwide. For Dr. Aleixo Muise and his team, this glow isn’t just a lab curiosity; it’s a beacon pointing toward precision medicine for a disease that affects 5 million people globally. Their discovery, published in Gastroenterology and forged through collaboration across eight countries, uncovers BIRC3 variants as a previously unknown genetic cause of Crohn’s and exposes a malfunction in the RIPK1 pathway, a critical regulator of inflammation tied to tumor necrosis factor (TNF). This isn’t just another genetic clue—it’s a druggable target, one that could reshape how doctors match patients to treatments.
Crohn’s disease, the most common form of inflammatory bowel disease (IBD), has been rising sharply worldwide, especially in younger populations. Canada already has one of the highest IBD rates on Earth, and by the early 2030s, one in every 100 Canadians is expected to live with the condition. At SickKids, clinicians care for about 1,500 IBD patients annually, including some as young as infancy—a trend that alarmed Muise a decade ago and now demands urgent answers. Current therapies fail half of patients, largely because IBD is driven by a tangled web of environmental, microbial, immune, and genetic factors. But for the 14 children identified with BIRC3 mutations, the cause is clear—and so may be the cure.
The journey began in 2019 when Muise’s lab zeroed in on BIRC3, a gene known to interact with the TNF pathway, already a cornerstone of IBD treatment. Despite pandemic disruptions, the team confirmed within two years that BIRC3 dysfunction leads to unchecked cell death and gut inflammation. Working with scientists from China, the U.S., Germany, Japan, France, Saudi Arabia, and Spain, they identified patients carrying the variant and used zebrafish and mouse models to validate the mechanism. In every case, the BIRC3 defect disabled a protective function in intestinal cells, leaving them vulnerable to damage. “Normally, BIRC3 protects cells in the intestine, but in all 14 patients they lost this function,” says Qi Li, senior research associate and first author. “This makes the gut more vulnerable to damage and raises the risk of Crohn’s disease.”
The discovery shifts the landscape for monogenic IBD, previously studied mostly in children under six. Now, with a defined pathway—RIPK1—drugs can be developed or repurposed to target the root cause. Some experimental compounds already in development for other conditions may fit the bill. For families who have waited years for answers, this isn’t just science—it’s hope with a molecular address. As Muise puts it, “We want to find the right drug for each person based on their body's unique signature.” With BIRC3 illuminated, that future feels closer than ever.